Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442168 in Non-relapsing Secondary Progressive Multiple Sclerosis
CTR20210121Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tolebrutinib in secondary-progressive multiple sclerosis (SPMS), sponsored by Sanofi. Started Jan 2021; status: completed.
02
Drugs
tolebrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on CTR20210121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210121.